iSTAR Medical was selected for a presentation at the virtual European Ophthalmology Futures Forum this Thursday 7 October, where CEO Michel Vanbrabant will present competitive strengths for iSTAR Medical’s revolutionary MIGS device MINIjectTM.
Session: Company Presentations 3
Time: 18:20 – 19:20 CEST
The clinical data show consistently positive safety and efficacy outcomes in a larger patient population from ongoing trials. “The next generation MIGS made of anti-fibrotic STAR material has shown powerful and sustained performance as well as safety in clinical studies to-date, which is promising for very long-term results for the treatment of patients with open-angle glaucoma,” Vanbrabant commented.
Ophthalmology Futures Forums are clinician-driven innovation meetings in the ophthalmic healthcare sector. They cover all aspects of global innovaion in ophthalmic devices, diagnostics and pharmaceuticals by connecting scientists, physicians, regulators, reimbursement specialists, corporate leaders, venture capitalists and other investors who support the advancement of eye care.